btk inhibitor 13

BTK inhibitor 13 (compound 8) is a potent and selective BTK inhibitor with an IC50 of 1.2 nM.

BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.

mTOR inhibitor 13 is a selective mTOR inhibitor with IC50 of 0.29nM and 119nM for mTOR and PI3Kα, respectively.

BTK inhibitor 17 is a potent irreversible Bruton’s tyrosine kinase (BTK) inhibitor with an IC50 value of 2.1 nM, suitable for use in rheumatoid arthritis studies.

TCS PrP Inhibitor 13 (5-(4-Nitrophenyl)-2-Phenyl-4H-Pyrazol-3-One) is an antiprion agent inhibiting protease-resistant prion protein (PrP-res) accumulation.

Chitin Synthase Inhibitor 13 (compound 12g), a non-competitive antagonist of chitin synthase, demonstrates broad-spectrum antifungal activity and has an inhibition concentration (IC50) of 106.7 μM [1].

DNA Primase Inhibitor-13 is a novel inhibitor of DNA primase.

BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC 50 = 2.7 nM).

P-gp Inhibitor 13, a P-glycoprotein antagonist, can counteract paclitaxel resistance in A2780 T cells, proving valuable for advanced acute myeloid leukemia research [1].

BTK inhibitor 20 is a potent BTK inhibitor with an IC [50 ] of 8 nM.

HIV-1 inhibitor-13 is an orally active HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an IC50 value of 0.14 μM against HIV-1 RT. HIV-1 inhibitor-13 is active against HIV-1 resistant strains (EC50: 2.85-18.0 nM).

PI3K/mTOR Inhibitor-13, an orally active dual inhibitor targeting phosphoinositol 3-kinase (PI3K) and mTOR kinase, holds potential for treating sexual diseases, solid tumors, and idiopathic pulmonary fibrosis (IPF).

Tubulin Inhibitor 13 (E27) effectively inhibits tubulin polymerization with an IC50 of 16.1 μM. This compound also restricts cancer cell migration and invasion, promotes apoptosis, and exhibits notable anticancer activity [1].

KRAS inhibitor-13 (compound 5-6) is a potent inhibitor of KRAS G12C (IC50: 0.883 μM) and demonstrates a p-ERK inhibitory effect in MIA PaCA-2 and A549 cells with IC50 values of 5.9 μM and >100 μM respectively. KRAS inhibitor-13 has potential applications in pancreatic, colorectal, and lung cancer studies.

Btk inhibitor 1 Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.IC50 value:Target: BtkFrom PCT Int. Appl. (2012), WO 2012158843 A2 20121122. [1]. PCT Int. Appl. (2012), WO 2012158843 A2 20121122.

MMP-9 MMP-13 Inhibitor I is a dual inhibitor of MMP-9 and MMP-13 with IC50 of 0.9 nM for both enzymes. It is over 20 times more selective for MMP-9 MMP-13 than for other MMPs.

Btk Inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.

ATX inhibitor 13 (compound 10c) is an orally active ATX inhibitor (IC50: 3.4 nM) that arrests the cell cycle of RAW264.7 cells in the G2 phase, inhibits cell proliferation and migration, induces apoptosis, and exhibits an inhibitory effect on tumour colony formation.

KRAS G12C Inhibitor 13 is a specific inhibitor targeting the KRAS G12C mutation.

KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D with potential for the investigation of KRAS G12D-mediated cancers.

Carbonic anhydrase inhibitor 13 (compound 7) is a potent inhibitor of carbonic anhydrase (CA).

Topoisomerase II inhibitor 13 inhibits topoisomerase II (Topo II) that shows strong anti-proliferation activity against HL-60/MX2 cancer cells derived from HL-60 against Topo II toxicity.

Mcl-1 Inhibitor 13 (Example 9), with a Ki of 8.2 nM, serves as an MCL-1 inhibitor suitable for cancer research [1].

BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.

BTK inhibitor 10 is a potent and orally active compound with potential applications in rheumatoid arthritis treatment.

LFM-A13（IC50=2.5 μM）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.